Policy
PAREA launches psychedelics manifesto for mental health in Europe

Published
2 months agoon

In a bid to help improve mental health care across Europe, the Psychedelic Access and Research European Alliance (PAREA) has launched a manifesto for the 2024 EU elections.
Europe is currently facing a mental health crisis, with an estimated 84 million people in the EU living with a mental health condition. With no innovation in care for mental health conditions in decades, there is a desperate need for new treatments.
With the recent rise of research into psychedelics having shown promising results, indicating these medicines could transform mental healthcare, PAREA launched in 2022 to help advance psychedelic healthcare across Europe.
This has led to a number of developments in Europe over the last year that has seen the EMA announce a workshop in European parliament to discuss psychedelic medicines and the call for a central, psychedelics advisory body to guide regulators and professionals on best practices and standardisation of care.
In light of these developments, non-profit PAREA has now launched its manifesto for the 2024 EU elections, which sets out priorities for the EU as it looks towards the potential rollout of psychedelic therapies in the future.
PAREA writes: “Our manifesto outlines the limitations of current mental health treatments and highlights the untapped potential of psychedelic therapies. It underscores the potential of psychedelic therapies to help individuals confront and understand the underlying issues contributing to their mental health conditions, as opposed to merely managing symptoms.
“Key to our manifesto is the call for an EU multidisciplinary task force. This proposed body can help to establish national guidelines for the responsible use of psychedelic therapies, bringing together healthcare professionals, patient organisations, regulators, psychedelic organizations, and other relevant stakeholders.
“As we approach the EU Parliament elections in 2024, this manifesto serves as an essential guide for anyone committed to advancing mental health care in Europe.”
Priorities for the EU in the manifesto include:
- Including novel mental health approaches in its policy agenda
- To support the development and meaningful regulation of psychedelic therapies
- Recognise the unique combination of psychedelic medicines and therapy, support future aftercare provision, and promote the adoption of sustainable integration models
- To foster collaboration and provide a platform and resources to aid in the development and implementation of effective and sustainable care provision models for psychedelic therapies
- To incentivise the development of psychedelic therapies and ensure their accessibility and affordability when they become approved
- Support healthcare practitioners to make psychedelic therapies part of their practice by providing adequate resources.
- Prioritise and fund basic research on psychedelic therapies under the Horizon Europe programme and other relevant research schemes
The manifesto reads: “In this pivotal moment for mental health care, we must seize the opportunity to explore and embrace innovative solutions like psychedelic therapies. As PAREA, we are committed to fostering dialogue, enhancing research, and supporting policy changes to usher in a new era of mental health treatment in Europe. Together, we can ensure a healthier, more compassionate future for all, and bring tangible benefits to your constituents who are currently underserved by existing mental health care solutions.”
To view the full manifesto, please click here.
You may like
Psychedelic therapy programmes launch to address heartbreak, burnout and more
Groundbreaking trial to assess real-world efficacy of MDMA therapy for PTSD
PAREA’s psychedelic push: improving policy for mental health innovation in Europe
Oakland ballot seeks to legalise medical psychedelics
European psychedelic initiative aims to impact education and regulation
Mental health improvements for veterans following psychedelic treatment
Policy
Now is the time for psychedelic access, says campaigner

Published
2 weeks agoon
21st November 2023By
News Editor
Activists in Oakland recently filed a ballot put forward by Dave Hodges seeking to legalise safe and legal access to psychedelics for therapeutic uses.
In the face of critics, Hodges has said now is the time for safe access to psychedelics.
The Psychedelic Wellness & Healing Initiative would enable the sale, possession and use of psychedelics for therapeutic purposes if passed. Psychedelics that would be allowed under the ballot include Psilocybin, MDMA, DMT, and Mescaline.
If passed, the initiative would give doctors and mental health specialists the right to recommend psychedelics to ease the debilitating symptoms of a range of problems, including obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), depression, anxiety, addiction, suicidality and traumatic brain injury (TBI), among others.
Hodges has said: “Now is the time for safe, controlled medical access for patients in need. The way to solve the problem is not by continuing to ignore it.”
Hodges’ solution is to create a structure for use that includes proper dosages and access to experts who can help users benefit from appropriate treatment.
The updated initiative language emphasises safety, and gives doctors and mental health specialists the right to recommend psychedelics to ease the debilitating symptoms of a range of conditions.
Research by the University of Michigan and Columbia University shows non-LSD hallucinogenic use on the rise and Hodges has stated that increase means that the initiative providing guidelines for use is needed more than ever.
Hodges said he hopes Californians will read the initiative, share their thoughts about it over the holiday week and offer feedback via the initiative website, PW4CA.com, by 27 November, 2023, the deadline for modifications.
“Now is the time to provide medical and therapeutic access to psychedelics,” Hodges said. “The way to do this is through the initiative.”
Policy
Transform Drugs releases groundbreaking book: How to regulate psychedelics

Published
3 weeks agoon
15th November 2023
UK charity Transform Drug Policy Foundation has published a new book ‘How to Regulate Psychedelics: A Practical Guide’ that sets out how psychedelics can be legalised and regulated for non-medical adult use.
While an increasing amount of research is pointing to the potentially beneficial effects of psychedelic treatment on mental health conditions, many people across the globe are using psychedelics outside of the clinical setting.
The book includes a set of proposals for post-prohibition policies, covering psychedelics including psilocybin, LSD, DMT and Mescaline.
Previously, Transform’s guides on regulating stimulants and cannabis have been used to advise governments around the world on drug policy. This book seeks to inform the debates on psychedelic drug reforms taking place across the world.
Co-author and Public Affairs and Policy Manager at Transform Drug Policy Foundation, Ester Kincová, stated: “Despite psychedelic drugs being illegal, their non-medical use within society has been steadily increasing.
“Punitive enforcement has not decreased use or eliminated supply, but it has made use more unsafe.
“Legalising and regulating psychedelics is a pragmatic move to reduce harm. This is no longer a theoretical debate, states in the US are already recognising the need and making moves to regulate for non-medical adult use.”
Scientific Chair of Drug Science, Professor David Nutt, added: “Once again Transform have come up with a well thought out and practical plan for the regulation of another group of currently illegal drugs – in this case psychedelics.
“Their ideas would be both easy to implement and to engage with and will, if adopted, radically enhance the safe use of these remarkable agents.”
Proposals for regulation
The book includes a four-tiered regulation model “that attempts to manage the variety of psychedelic preparations and the different ways in which they are used”.
These include:
- Private use, home cultivation, foraging and not-for-profit sharing.
- Membership-based non-for-profit associations for plant-based products.
- Licensed production and retail adaptable to different products and environments
- Regulated commercial guided or supervised use
Additionally, a decriminalisation model is proposed which suggests that possession for personal use should no longer be an offence of any kind or be subject to any sanctions; Drugs for personal use should not be confiscated; cultivation of small amounts of plant-based drugs for personal use should be decriminalised, among other suggestions.
The book also includes topics such as embedding social justice, equity and human rights into policy design, how to think about psychedelics regulation, why regulate psychedelics and why now, and psychedelics and the UN drug treaties.
To read the book, please visit transformdrugs.org/.
Policy
Oakland ballot seeks to legalise medical psychedelics

Published
1 month agoon
30th October 2023By
News Editor
Activists in Oakland have filed a ballot that seeks to legalise safe and legal access to psychedelics for therapeutic uses.
The Psychedelic Wellness & Healing Initiative would enable the sale, possession and use of psychedelics for therapeutic purposes if passed. Psychedelics that would be allowed under the ballot include Psilocybin, MDMA, DMT, and Mescaline.
If passed, the initiative would give doctors and mental health specialists the right to recommend psychedelics to ease the debilitating symptoms of a range of problems, including obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), depression, anxiety, addiction, suicidality and traumatic brain injury (TBI), among others.
Additionally, it would create a statewide framework for regulating the possession, use, cultivation and production of substances for medical and therapeutic use.
The initiative has been introduced by proponent and founder of the Oakland-based Church of Ambrosia, Dave Hodges, to the California Attorney General’s office for the 2024 ballot, and will need 546,651 valid signatures to qualify.
The filing follows California Governor Gavin Newsom’s recent veto of Senate Bill 58, the bill that sought to decriminalise the use of certain psychedelic drugs.
Hodges emphasised that SB58 would have been a step forward, but that it had major flaws concerning its lack of provisions to ensure access, public safety and quality control. That veto, Hodges said, compelled him to move quickly on the initiative filing.
When the California Attorney General certifies the initiative for circulation, backers will have about four and a half months to gather the required signatures for ballot placement.
Signature collecting will begin in early December.
Recent Articles
- Mapping the effects of ketamine on the brain
- Psychedelic therapy programmes launch to address heartbreak, burnout and more
- Psilocybin analogue shows positive results in Phase 2 depression study
- Ketamine: understanding the K-Hole
- Mychedelica launches to revolutionise psychedelic medicine
- Clerkenwell Health calls for volunteers to support groundbreaking psychedelic research
Trending
- Psychedelic therapy programmes launch to address heartbreak, burnout and more
- Psilocybin analogue shows positive results in Phase 2 depression study
- Ketamine: understanding the K-Hole
- Mychedelica launches to revolutionise psychedelic medicine
- Clerkenwell Health calls for volunteers to support groundbreaking psychedelic research
Trending
- Opinion2 years ago
Clerkenwell Health is launching a free UK psychedelic therapist training programme
- Insight2 years ago
Mixing psychedelics with lithium poses significant risk of seizures
- Medicinal2 years ago
MDMA therapy for PTSD granted innovation passport by UK
- Research2 years ago
LSD trial for the treatment of adult ADHD initiated
- Markets & Industry12 months ago
Where can I find training for psychedelic therapy?
- Medicinal2 years ago
MDMA: the love drug?
- News2 years ago
Awakn’s second psychedelic therapy clinic to open in London
- Research2 years ago
London to host Europe’s first commercial psychedelic clinical trial facility